TOLERO PHARMACEUTICALS
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

TOLERO PHARMACEUTICALS Trademark

Serial Number: 79212382 • Registration: 5505386

TOLERO PHARMACEUTICALS is a trademark filed by Sumitomo Dainippon Pharma Co., Ltd. on March 22, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Sumitomo Dainippon Pharma Co., Ltd.

6-8, Doshomachi 2-chome,

Entity Type: 03

Trademark Details

Filing Date

March 22, 2017

Registration Date

July 3, 2018

Published for Opposition

April 17, 2018

Cancellation Date

January 17, 2025

Goods & Services

Providing medical information

Pharmaceutical preparations, namely, anti-inflammatories; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the central nervous system, namely, diseases of the brain, movement, ocular motility and spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy and Parkinson's disease and central nervous systems infections; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the peripheral nervous system, namely, amyotrophic lateral sclerosis, numbness, lightheadedness, dysuria and dyshidrosis; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the respiratory system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the urogenital system, namely, urological diseases, infertility, sexually transmitted diseases and inflammatory pelvic diseases; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the cardiovascular system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the endocrine system, namely, growth and thyroid disorders; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the metabolic system, namely, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the renal system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the gastroenterological system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the ophthalmologic system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the dermatologic system, namely, dermatitis, eczema, psoriasis, skin pigmentation diseases and sexually transmitted diseases; pharmaceutical preparations for the prevention and treatment of hematologic and oncologic disorders and diseases; pharmaceutical preparations for the prevention and treatment of psychiatric disorders and diseases, namely, anxiety disorders, mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, Parkinson's disease, Alzheimer's disease, cerebral palsy, multiple sclerosis and seizures; pharmaceutical preparations for the prevention and treatment of allergic disorders and diseases and disorders and diseases of the immune system, namely, autoimmune diseases and immunologic deficiency syndromes; pharmaceutical preparations for the prevention and treatment of connective tissue and joints, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures and cartilage injuries; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for use in chemotherapy

Filing History

TOTAL INVALIDATION PROCESSED BY THE IB
Mar 19, 2026 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Feb 28, 2026 INTS
INVALIDATION PROCESSED
Feb 28, 2026 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Sep 17, 2025 INTR
CANCELLED SECTION 71
Jan 17, 2025 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jul 3, 2023 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 26, 2018 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 4, 2018 FICS
FINAL DISPOSITION PROCESSED
Oct 4, 2018 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 3, 2018 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 3, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 17, 2018 NPUB
PUBLISHED FOR OPPOSITION
Apr 17, 2018 PUBO
NOTIFICATION PROCESSED BY IB
Apr 13, 2018 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 28, 2018 OPNS
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 28, 2018 NONP
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 28, 2018 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 15, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 14, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 13, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 13, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 22, 2017 GNRN
NON-FINAL ACTION E-MAILED
Dec 22, 2017 GNRT
NON-FINAL ACTION WRITTEN
Dec 22, 2017 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 19, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 19, 2017 CRFA
ASSIGNED TO LIE
Dec 15, 2017 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 7, 2017 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 8, 2017 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 8, 2017 REAP
REFUSAL PROCESSED BY IB
Aug 12, 2017 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 27, 2017 RFCS
REFUSAL PROCESSED BY MPU
Jul 27, 2017 RFRR
APPLICATION FILING RECEIPT MAILED
Jul 25, 2017 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 21, 2017 RFCR
NON-FINAL ACTION WRITTEN
Jul 20, 2017 CNRT
ASSIGNED TO EXAMINER
Jul 19, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 19, 2017 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jul 14, 2017 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 13, 2017 REPR